NCT00865566: A trial that was reported late by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported, although it was 2 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT00865566 |
|---|---|
| Title | Phase 2b, Randomized, Placebo-Controlled Test-of-Concept Trial to Evaluate the Safety and Efficacy of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by a Multiclade HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Adenovirus Type 5 Neutralizing Antibody Negative, Circumcised Men and Male-to-Female (MTF) Transgender Persons, Who Have Sex With Men |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | May 31, 2009 |
| Completion date | Oct. 6, 2017 |
| Required reporting date | Oct. 6, 2018, midnight |
| Actual reporting date | Oct. 8, 2018 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | 2 |